LEPU BIO-B Releases 2025 Board Package, Maintains Zero Dividend and Seeks 20% Share Issuance Mandate

Bulletin Express04-27 21:23

LEPU BIO-B (Lepu Biopharma Co., Ltd.) has distributed its 2025 annual general-meeting (AGM) circular, setting out key proposals for shareholder approval on 19 May 2026 in Beijing.

Key AGM Items 1. 2025 Performance Documents • Board and Supervisory reports, full annual report and financial statements for FY-2025 will be tabled. • The company recorded “no profit available for distribution”; accordingly, the 2025 profit-distribution plan recommends neither a cash dividend nor a capital-reserve conversion.

2. 2026 Financial Budget • Resources will be directed to product commercialisation, clinical trials and daily operations. No quantitative budget targets were disclosed in the circular.

3. Capital-Market Actions • General mandate: the Board seeks authority to issue up to 360.89 million additional H-shares—20% of the existing 1.80 billion share base—during the mandate period. • Re-appointment of Ernst & Young as auditor for FY-2026 at an estimated audit fee of RMB2.90 million.

4. Governance Updates • Proposed appointment of Ms Fan Xinyu as supervisor with an annual remuneration of RMB0.15 million, succeeding the retiring Mr Yang Ming. • Proposal to move the company’s registered address to Block 4, No. 651 Lianheng Road, Minhang District, Shanghai. • Corresponding amendments to the Articles of Association reflect the new address.

Procedural Details • The H-share register will be closed from 14 May to 19 May 2026 for AGM eligibility. • Shareholders may vote by proxy; all resolutions will be decided by poll.

The Board recommends approval of all proposals, citing alignment with the company’s operational needs and strategic objectives.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment